Developer docs
API playgroundTry for free, no card

Search company profiles

Eyenovia

Full company profile

uuid0002lwm

Namestring
Eyenovia
Legal namestring
Eyenovia, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Eyenovia, Inc. was originally founded in 2014 as a biopharmaceutical company developing a portfolio of next-generation topical eye treatments built around its proprietary Optejet platform — a microdroplet ophthalmic drug delivery device designed for precise, controlled topical dosing versus traditional eye drops. Approved and pipeline products included Mydcombi (a topical mydriatic/miotic agent for ophthalmic surgical procedures) and MicroLine (a presbyopia treatment in development). The company pursued a direct field-sales commercialization model targeting ophthalmologists and optometrists in U.S. clinical and commercial channels.

In September 2024, Eyenovia was acquired by Armistice Capital LLC and effectively pivoted from ophthalmic drug delivery to a decentralized finance (DeFi) strategy. The public entity now operates as Hyperion DeFi, Inc. (OTC: HYPD), with its core proposition being exposure to Hyperliquid's native HYPE token via a corporate treasury structure — bridging public markets and onchain strategies. The company has no disclosed operating revenue under the new model; its economics depend on token price appreciation rather than product sales. Headcount is 11-50, the company is led by CEO Hyunsu Jung (formerly DARMA Capital, EY-Parthenon) since January 2026, and has raised approximately $76 million in post-pivot equity rounds between June 2024 and May 2026, with Armistice Capital as controlling shareholder and largest historical investor.

Short descriptiontext

Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) is a public company operating a corporate treasury strategy that provides public-market exposure to Hyperliquid's native HYPE token, following its September 2024 acquisition by Armistice Capital and pivot away from ophthalmic drug delivery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ophthalmic drug delivery, topical eye treatments, microdose dispensing, presbyopia therapeutics, ophthalmic pharmaceuticals
Industry2 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Pharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales
TypeHardware Sales
Description

Commercialization of ophthalmic products including Mydcombi and the Optejet platform devices for clinical and commercial use

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eyenovia developed and commercialized a portfolio of next-generation topical ophthalmic treatments built on its proprietary Optejet microdroplet drug-delivery platform. Its commercial offering, Mydcombi, is an FDA-approved topical ophthalmic solution for inducing mydriasis or miosis during ophthalmic surgical procedures, while MicroLine (in development) targets presbyopia. The company sold these products and devices to ophthalmology and optometry practices in the United States.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eyenovia is an ophthalmic pharmaceutical and drug delivery technology company that developed and commercialized ophthalmic products and devices. The company operated a portfolio including the Optejet micro-dose ophthalmic delivery platform, Mydcombi (a topical mydriatic/miotic agent), and MicroLine (a presbyopia treatment). The company's technology focused on precise, topically-administered ophthalmic drug delivery for various eye conditions and surgical applications.

Product and service1 record
1Optejet
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alcon is the largest dedicated ophthalmic company globally, offering surgical, pharmaceutical, and vision care products. Comparable as a broad incumbent whose pharmaceutical franchise competes directly with Eyenovia's Mydcombi in cataract/mydriasis applications and whose surgical-channel relationships overlap with Eyenovia's commercialization targets.

TypeDirect peer
Description

Clearside Biomedical developed the suprachoroidal SpacePort delivery platform (XIPERE for macular edema) and partners on gene therapy delivery to the back of the eye. Comparable as a small-cap ophthalmic drug delivery innovator targeting retina specialists with platform technology.

TypeBroad incumbent
Description

Bausch + Lomb is a global ophthalmic incumbent with branded pharmaceuticals (including Bausch & Lomb where Eyenovia board director Dr. Strahlman previously served as CMO), surgical devices, and consumer vision care. Comparable as a broad incumbent operating across the same ophthalmic prescribing channels where Eyenovia's Mydcombi and MicroLine compete.

TypeEmerging player
Description

Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab), an ophthalmic formulation for wet AMD targeting retinal specialists. Comparable as a small-cap ophthalmic pharma pursuing a single late-stage approval with similar capital-raise dynamics to Eyenovia's pre-pivot profile.

TypeDirect peer
Description

Ocular Therapeutix develops hydrogel-based sustained-release drug delivery (DEXTENZA for post-surgical inflammation). Closely comparable to Eyenovia as a small-cap ophthalmic platform company with approved products built around proprietary drug-delivery technology addressing eye care specialists.

TypeDirect peer
Description

Aldeyra Therapeutics is a clinical-stage ophthalmic pharmaceutical company developing treatments for dry eye disease and other ocular inflammatory conditions. Comparable as a small-cap, late-clinical-stage ophthalmic pharma company with similar funding dynamics and specialty-pharma channel.

TypeDirect peer
Description

Nicox is a European ophthalmic company focused on glaucoma therapeutics (VYZULTA, NCX 470). Comparable to Eyenovia as a small ophthalmic specialty pharma developing novel topical therapeutics for ophthalmologists and optometrists.

TypeDirect peer
Description

EyePoint Pharmaceuticals develops sustained-release ocular drug delivery technologies (DURYSTA, YUTIQ) for conditions including glaucoma and retinal disease. Directly comparable to Eyenovia's Optejet platform as both companies commercialize novel ophthalmic drug delivery systems targeting the same specialty physician channel.

TypeEmerging player
Description

Kala Bio is a clinical-stage ophthalmic company developing novel therapies for rare eye diseases using a proprietary mucus-penetrating particle technology. Comparable as a small-cap, technology-platform-driven ophthalmic pharma targeting specialist prescribers.

TypeOthers
Description

Following the 2024 pivot, Eyenovia/Hyperion DeFi is most comparable to other public crypto-treasury companies (e.g., MicroStrategy for BTC, newer HYPE/SOL treasury wrappers) that raise dilutive equity to acquire and hold digital assets. Different business model than the original ophthalmic operations.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eyenovia

Ophthalmic Pharmaceuticalshyperiondefi.com

Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) is a public company operating a corporate treasury strategy that provides public-market exposure to Hyperliquid's native HYPE token, following its September 2024 acquisition by Armistice Capital and pivot away from ophthalmic drug delivery.

What Eyenovia does

Eyenovia, Inc. was originally founded in 2014 as a biopharmaceutical company developing a portfolio of next-generation topical eye treatments built around its proprietary Optejet platform — a microdroplet ophthalmic drug delivery device designed for precise, controlled topical dosing versus traditional eye drops. Approved and pipeline products included Mydcombi (a topical mydriatic/miotic agent for ophthalmic surgical procedures) and MicroLine (a presbyopia treatment in development). The company pursued a direct field-sales commercialization model targeting ophthalmologists and optometrists in U.S. clinical and commercial channels.

In September 2024, Eyenovia was acquired by Armistice Capital LLC and effectively pivoted from ophthalmic drug delivery to a decentralized finance (DeFi) strategy. The public entity now operates as Hyperion DeFi, Inc. (OTC: HYPD), with its core proposition being exposure to Hyperliquid's native HYPE token via a corporate treasury structure — bridging public markets and onchain strategies. The company has no disclosed operating revenue under the new model; its economics depend on token price appreciation rather than product sales. Headcount is 11-50, the company is led by CEO Hyunsu Jung (formerly DARMA Capital, EY-Parthenon) since January 2026, and has raised approximately $76 million in post-pivot equity rounds between June 2024 and May 2026, with Armistice Capital as controlling shareholder and largest historical investor.

Eyenovia firmographics

Firmographics
Name
Eyenovia
Legal name
Eyenovia, Inc.
Website
https://hyperiondefi.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) is a public company operating a corporate treasury strategy that provides public-market exposure to Hyperliquid's native HYPE token, following its September 2024 acquisition by Armistice Capital and pivot away from ophthalmic drug delivery.
Ownership category
akta.pro rank

Eyenovia industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Ophthalmic drug delivery
  • Topical eye treatments
  • Microdose dispensing
  • Presbyopia therapeutics
  • Ophthalmic pharmaceuticals

Where Eyenovia is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Eyenovia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations

Revenue model

  1. Product Sales: Commercialization of ophthalmic products including Mydcombi and the Optejet platform devices for clinical and commercial use

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Eyenovia product offering

Product offering

Core offering

Eyenovia developed and commercialized a portfolio of next-generation topical ophthalmic treatments built on its proprietary Optejet microdroplet drug-delivery platform. Its commercial offering, Mydcombi, is an FDA-approved topical ophthalmic solution for inducing mydriasis or miosis during ophthalmic surgical procedures, while MicroLine (in development) targets presbyopia. The company sold these products and devices to ophthalmology and optometry practices in the United States.

Product overview

Eyenovia is an ophthalmic pharmaceutical and drug delivery technology company that developed and commercialized ophthalmic products and devices. The company operated a portfolio including the Optejet micro-dose ophthalmic delivery platform, Mydcombi (a topical mydriatic/miotic agent), and MicroLine (a presbyopia treatment). The company's technology focused on precise, topically-administered ophthalmic drug delivery for various eye conditions and surgical applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Optejet

Companies that use Eyenovia

Customer profile

Segments1 record

Ideal customer profiles1 record

Eyenovia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Eyenovia partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Eyenovia competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Alcon is the largest dedicated ophthalmic company globally, offering surgical, pharmaceutical, and vision care products. Comparable as a broad incumbent whose pharmaceutical franchise competes directly with Eyenovia's Mydcombi in cataract/mydriasis applications and whose surgical-channel relationships overlap with Eyenovia's commercialization targets.
  • Bausch + Lomb: Bausch + Lomb is a global ophthalmic incumbent with branded pharmaceuticals (including Bausch & Lomb where Eyenovia board director Dr. Strahlman previously served as CMO), surgical devices, and consumer vision care. Comparable as a broad incumbent operating across the same ophthalmic prescribing channels where Eyenovia's Mydcombi and MicroLine compete.

Direct peers

  • Clearside Biomedical: Clearside Biomedical developed the suprachoroidal SpacePort delivery platform (XIPERE for macular edema) and partners on gene therapy delivery to the back of the eye. Comparable as a small-cap ophthalmic drug delivery innovator targeting retina specialists with platform technology.
  • Ocular Therapeutix: Ocular Therapeutix develops hydrogel-based sustained-release drug delivery (DEXTENZA for post-surgical inflammation). Closely comparable to Eyenovia as a small-cap ophthalmic platform company with approved products built around proprietary drug-delivery technology addressing eye care specialists.
  • Aldeyra Therapeutics: Aldeyra Therapeutics is a clinical-stage ophthalmic pharmaceutical company developing treatments for dry eye disease and other ocular inflammatory conditions. Comparable as a small-cap, late-clinical-stage ophthalmic pharma company with similar funding dynamics and specialty-pharma channel.
  • Nicox SA: Nicox is a European ophthalmic company focused on glaucoma therapeutics (VYZULTA, NCX 470). Comparable to Eyenovia as a small ophthalmic specialty pharma developing novel topical therapeutics for ophthalmologists and optometrists.
  • EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery technologies (DURYSTA, YUTIQ) for conditions including glaucoma and retinal disease. Directly comparable to Eyenovia's Optejet platform as both companies commercialize novel ophthalmic drug delivery systems targeting the same specialty physician channel.

Emerging players

  • Outlook Therapeutics: Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab), an ophthalmic formulation for wet AMD targeting retinal specialists. Comparable as a small-cap ophthalmic pharma pursuing a single late-stage approval with similar capital-raise dynamics to Eyenovia's pre-pivot profile.
  • Kala Bio: Kala Bio is a clinical-stage ophthalmic company developing novel therapies for rare eye diseases using a proprietary mucus-penetrating particle technology. Comparable as a small-cap, technology-platform-driven ophthalmic pharma targeting specialist prescribers.

Others

  • Hyperliquid Strategies / similar crypto treasury vehicles: Following the 2024 pivot, Eyenovia/Hyperion DeFi is most comparable to other public crypto-treasury companies (e.g., MicroStrategy for BTC, newer HYPE/SOL treasury wrappers) that raise dilutive equity to acquire and hold digital assets. Different business model than the original ophthalmic operations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Eyenovia social profiles

Digital presence

Eyenovia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eyenovia leadership team

Management profile

Number of profiles

Profiles13 records

Eyenovia funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eyenovia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyenovia

What does Eyenovia do?

Eyenovia developed and commercialized a portfolio of next-generation topical ophthalmic treatments built on its proprietary Optejet microdroplet drug-delivery platform. Its commercial offering, Mydcombi, is an FDA-approved topical ophthalmic solution for inducing mydriasis or miosis during ophthalmic surgical procedures, while MicroLine (in development) targets presbyopia. The company sold these products and devices to ophthalmology and optometry practices in the United States.

Is Eyenovia a public or private company?

Eyenovia is a public company. It is classified as private equity controlled and is currently operating.

When was Eyenovia founded?

Eyenovia was founded in 2014. It employs 1 to 10 people.

Where is Eyenovia based?

Eyenovia is headquartered in New York, United States, in the North America region.

How does Eyenovia make money?

One revenue line is on record: product Sales.

Who are Eyenovia's main competitors?

Broad incumbents on record are Alcon and Bausch + Lomb. Direct peers are Clearside Biomedical, Ocular Therapeutix, Aldeyra Therapeutics, Nicox SA and EyePoint Pharmaceuticals. Emerging players are Outlook Therapeutics and Kala Bio. Hyperliquid Strategies / similar crypto treasury vehicles is listed as an others.

Does Eyenovia have an API?

No public API is recorded for Eyenovia.

What industry is Eyenovia in?

Eyenovia's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePresbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightDelveInsight's presbyopia market report projects growth at a CAGR of 4.9% from 2026 to 2036, with the market valued at USD 11 billion across the seven major markets (7MM) in 2025. The United States holds the largest market share at 50%, driven by an aging global population, increasing prevalence of age-related near vision impairment, and a growing treatment landscape. Key companies including AbbVie, LENZ Therapeutics, Tenpoint Therapeutics, and multiple firms developing pipeline therapies such as Phentolamine (Opus Genetics/Viatris), MicroLine (Eyenovia), GLK-302 (Glaukos Corporation), and CorVision (LinkoCare Life Sciences AB) are actively advancing treatments expected to reshape the market.openPR.comAnalysis of Segments and Major Growth Areas in the Post-Operative Cataract Surgery Inflammation Treatment MarketThe post-operative cataract surgery inflammation treatment market is projected to reach $6.78 billion by 2030, growing at a 7.2% CAGR, driven by rising demand for advanced ophthalmic drug formulations and increased investments in ophthalmology research. In September 2024, Armistice Capital LLC acquired Eyenovia Inc., strengthening its position in the ophthalmic field. In March 2024, Taiwan's Formosa Pharmaceuticals, in partnership with AimMax Therapeutics, received FDA approval for APP13007 (clobetasol propionate ophthalmic suspension 0.05%), the first new ophthalmic steroid approved by the FDA in over 15 years.openPR.comSegmentation, Major Trends, and Competitive Overview of the Ophthalmic Eye Dropper MarketThe Business Research Company released a market report projecting the ophthalmic eye dropper market to reach $20.07 billion by 2030, growing at a CAGR of 6.9%, driven by demand for enhanced drug delivery systems, an aging population, and advances in preservative-free formulations. In April 2023, Nirma Group acquired Stericon Pharma Pvt. Ltd. to strengthen its healthcare portfolio and CDMO capabilities in the eye dropper segment. In May 2023, Hyperion DeFi Inc. launched MydCombi using its Optejet microdose platform, integrated with Eyenovia's drug-device technology, to improve dosing accuracy and patient compliance.EIN PresswireLA Employment Law Firm, Makarem & Associates files sexual harassment suit against EYENOVIA, INC. dba HYPERION DEFI, INC.Makarem & Associates, a Los Angeles-based employment law firm, filed a sexual harassment lawsuit on November 4, 2025, in the Superior Court of California, County of Orange against EYENOVIA, INC. dba HYPERION DEFI, INC., an ophthalmic technology corporation. The complaint alleges that the company's CEO, Michael Rowe, accessed a plaintiff's personal cell phone without permission and secretly sent explicit images and videos of the plaintiff to himself during work hours on company premises. The lawsuit further alleges that after the plaintiff reported Rowe's misconduct to HR, the company failed to take all reasonable steps to prevent discrimination and harassment from occurring.SubstackDigital Asset Treasuries vs Crypto Venture Funding in 2025Digital Asset Treasury companies have raised over $15 billion in 2025 (through August 21), surpassing traditional crypto venture funding of approximately $6-8 billion, representing a significant shift in crypto capital allocation toward on-balance-sheet crypto holdings. The trend is driven by U.S. fair-value accounting rules (FASB ASU 2023-08), NAV premiums that enable cost-efficient capital raising, and instant liquidity advantages over illiquid venture investments. Key DAT issuers including MicroStrategy (Strategy), Mill City Ventures, ALT5 Sigma, Verb Technology, and Eyenovia have deployed capital primarily into Bitcoin, Ethereum, Hyperliquid, Solana, and Toncoin, with stock price reactions showing average +38% abnormal returns on announcement day, though post-deployment performance has been mixed.CoinSpeakerHYPE Falls 20% After Hyperliquid Treasury News DisappointsHYPE fell 20% after Hyperliquid treasury news disappointed, with technical support at $38.13. Eyenovia allocated $50 million and Lion Group secured $600 million for HYPE treasuries, but selling pressure continued.VerificationEyenovia 斥资 5000 万美元建立 HYPE 储备,公司将更名为「Hyperion DeFi」Nasdaq-listed digital ophthalmic technology company Eyenovia completed a $50 million PIPE financing to purchase Hyperliquid's native token HYPE and plans to become one of its main global validation nodes, with total fundraising cap expected to reach $150 million.BenzingaEyenovia (EYEN) Stock Explodes Following Amended Loan Agreement Terms: What's Going On?Eyenovia Inc (NASDAQ:EYEN) shares surged 40.4% to $2.92 during Thursday's trading session following disclosure of a third amendment to its loan and security agreement with lenders including Avenue Capital Management II, L.P., Avenue Venture Opportunities Fund, L.P., and Avenue Venture Opportunities Fund II, L.P. The amendment introduces a beneficial ownership limitation preventing lenders from converting principal into common stock if they would beneficially own more than 9.99% of outstanding shares, though lenders may request to increase this cap to 19.99% with 61 days notice.BenzingaEyenovia (EYEN) Shares Explode On Betaliq Merger Progress, Strong Q1 FinancialsEyenovia Inc (NASDAQ:EYEN) shares surged 38.9% after the company announced an extension of exclusive merger negotiations with Betaliq until June 7, 2025, and reported a significantly narrower first-quarter net loss of $3.5 million compared to $10.9 million a year earlier. Operating expenses fell 70% year-over-year following restructuring and a new debt agreement that defers repayments. The company also confirmed it remains on track to file for U.S. regulatory approval of its Optejet user-filled device in September.